252 related articles for article (PubMed ID: 36458459)
1. Significance of regulatory T cells in cancer immunology and immunotherapy.
Sugiyama D; Hinohara K; Nishikawa H
Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
[TBL] [Abstract][Full Text] [Related]
2. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
Togashi Y; Shitara K; Nishikawa H
Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
[TBL] [Abstract][Full Text] [Related]
7. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
[TBL] [Abstract][Full Text] [Related]
8. Redox modulation with a perfluorocarbon nanoparticle to reverse Treg-mediated immunosuppression and enhance anti-tumor immunity.
Li Z; Deng Y; Sun H; Tan C; Li H; Mo F; Wang Y; Li J; Zhou Z; Sun M
J Control Release; 2023 Jun; 358():579-590. PubMed ID: 37172908
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.
Kumagai S; Itahashi K; Nishikawa H
Nat Rev Clin Oncol; 2024 May; 21(5):337-353. PubMed ID: 38424196
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
12. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
13. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of Cancer by Targeting Regulatory T cells.
Chen BJ; Zhao JW; Zhang DH; Zheng AH; Wu GQ
Int Immunopharmacol; 2022 Mar; 104():108469. PubMed ID: 35008005
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
16. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
17. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
18. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T-cell development in the tumor microenvironment.
Itahashi K; Irie T; Nishikawa H
Eur J Immunol; 2022 Aug; 52(8):1216-1227. PubMed ID: 35879813
[TBL] [Abstract][Full Text] [Related]
20. Metabolic advantages of regulatory T cells dictated by cancer cells.
Kondo M; Kumagai S; Nishikawa H
Int Immunol; 2024 Feb; 36(2):75-86. PubMed ID: 37837615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
